What Does Microdosing GLP-1 Cost?

Cost is the single biggest reason anyone microdoses a GLP-1 drug. The pitch is simple: instead of paying brand-name prices for a full therapeutic dose, you stretch a cheaper compounded vial across many small fractional doses and pay a fraction of the monthly cost. This page lays out what microdosing GLP-1 actually costs across the routes people use — and, just as importantly, what the low sticker price hides. Read it as a buyer's-guide reality check, not an endorsement: there is no FDA-approved microdose of any GLP-1 drug, and the cheapest routes are also the least regulated.

Before the numbers, one framing fact the marketing skips: a "microdose" is a self-selected amount below even the lowest FDA-approved starting dose, so it is never sold to you as a finished, approved product ¹. Every price below is therefore the price of an off-label, do-it-yourself arrangement.

The two cost worlds: brand vs compounded

There are really two price tiers, and they're far apart.

Brand-name GLP-1 drugs — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — used to be the expensive tier by a wide margin, and that high price is precisely the pressure that created the microdosing market in the first place ². The list prices are still high: TrumpRx shows original prices of $1,349 a month for Wegovy, $1,087 for Zepbound and $1,028 for Ozempic ⁸. But the manufacturers' own self-pay programs have cut what an uninsured buyer actually pays. These are the self-pay prices we read on October 2, 2026:

• •Wegovy pill (oral semaglutide): $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg ¹⁰.
• •Wegovy injection: $199 a month for the first two fills of 0.25 mg or 0.5 mg for new patients, through December 31, 2026, then $349 a month up to 2.4 mg and $399 for the 7.2 mg dose ¹⁰.
• •Ozempic: the same $199 for the first two low-dose fills, then $349 a month up to 1 mg and $499 for 2 mg ⁸.
• •Zepbound single-dose vials: $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg to 15 mg if you refill within 45 days; otherwise $499 to $699 ⁹.

So brand self-pay now runs roughly $149 to $499 a month on these programs, and the lowest strengths are the cheapest ones. These are offers with eligibility rules and end dates, not list prices, and they exclude people with government insurance.

Compounded GLP-1 — mixed by a pharmacy rather than manufactured as the branded finished drug — is the cheaper tier, which is exactly why the direct-to-consumer market for it exploded during the GLP-1 shortage ^2,3. Compounded semaglutide and tirzepatide from telehealth platforms commonly advertise in the $155 to $500 per month range, and a microdosing approach (drawing smaller fractional amounts from a vial) is marketed as stretching that even further. The savings are real on paper. The catch is everything that comes bundled with the compounded supply chain — which we get to below.

Where the "microdose makes it even cheaper" math comes from

The microdosing cost logic is straightforward arithmetic: if a compounded vial contains, say, several full doses' worth of drug, and you draw a small fraction each time, one vial lasts many more weeks than it would at a full therapeutic dose. Spread the vial's price across more doses and the per-week cost drops. That's the entire financial appeal, and it's why microdosing is discussed almost exclusively in the context of cost-driven compounding rather than any clinical recommendation ¹.

That arithmetic has a hole in it, and it is the largest hidden cost in microdosing. A vial is not simply a quantity of drug — it is a quantity of drug with a discard date, assigned by the compounding pharmacy that made it and printed on the label. A 10 mg vial holds forty 0.25 mg microdoses; it does not hold them for forty weeks. Once it is reconstituted the clock starts, and at a small enough dose that date arrives with most of the vial still in it. Drug you throw away is drug you paid for, so the real cost of a milligram that reaches you can be several times the figure the vial price implies. A full-dose buyer never sees this, because they finish the same vial inside the same window and waste nothing — which is precisely why no general cost guide mentions it. Run it on your own vial and your own label: how much of the vial actually reaches you before its discard date.

The catch is that providers here do not sell you the vial — they sell you a monthly plan, and a monthly plan does not get cheaper when you take less out of the vial. The structural version of that question — which providers actually bill you less for taking less, and which merely sell a product called a microdose — is worked through provider by provider in who charges less when you take less. That gap is measurable rather than rhetorical: put your own dose and the dose range your plan says its single price covers into the arithmetic of a flat monthly rate at a deliberately small dose and it will tell you what share of the bill buys drug that is never dispensed to you. That single fact reorders the whole market for a low-dose buyer, which is why we rank providers on it directly — every ranking on this site is indexed here, with the question each one answers — in the cheapest tirzepatide for microdosing and the cheapest semaglutide for microdosing: the question those pages ask is not who is cheapest per month, but who actually charges you less for taking less. There is a third molecule and it is worth knowing about for a reason that has nothing to do with price — liraglutide is injected daily rather than weekly, so a dose that turns out to be too much has a one-day tail instead of a seven-day one, which is the finest control anyone sells for this. Hardly anybody stocks it, and the few sellers who publish a liraglutide price are here. Every answer exists in the wild: Lttl sells its microdose as a separate, cheaper product line, while WePeptideRx prices its microdose above its own starting standard dose — the same question, answered in opposite directions. A third answer is worth knowing because it is the one stated most plainly: MyDrHank promises in writing that the price never moves as you titrate, which is precisely the commitment you want if you expect to work upward, and precisely the structure that overcharges you if you never do — it sells no low-dose product at all, so a quarter dose is billed at the full plan's rate. The bluntest demonstration of that structure we have found is a company that asks you the dose and then ignores your answer: Synergy Rx collects a weekly semaglutide strength in five steps, from a quarter of a milligram up to two and a half, and its checkout has no dose dimension for that answer to change, so the smallest strength on its own form and the largest are billed the identical figure — for a tenth of the drug.

The trap worth naming separately is the one that looks like the good answer. A provider can build a genuine microdose product — its own SKU, its own funnel, its own consent step — and still not charge you less for it: SkinnyRx prices its microdose level with its own full-dose plans, matching them at every term the two share, and because its microdose line stops at a shorter commitment than its full-dose line, the cheapest rate a microdoser there can reach is the higher of the two. The existence of a named low-dose product tells you nothing about its price. Read the ladder, not the label. The clearest counter-example we have found runs the other way: Auren Rx charges $149 a month for microdose semaglutide against $199 for its own standard plan, and $250 against $299 on tirzepatide — a real discount on both molecules, at both commitment levels, which is rarer than it should be.

One check comes before all of those, though, and it is whether the headline is a month at all. Pallas Health advertises a monthly average that is really a twelve-week prepay divided by three: no month-to-month rung is published for either molecule, no dose selector appears anywhere before you pay, and so there is no low dose to price in the first place. A figure quoted per month by a plan that only ever bills per quarter is not comparable with a genuine monthly rate, and the cycle it renews on — every eighty-four days rather than every calendar month — makes it cost more over a year than dividing by three suggests. Before you ask whether a provider charges less for less, check that the number you are comparing covers the period it claims to. Sometimes there is no period to check against at all: Oak advertises nine different "starting" figures across its own pages and attaches a term or a billing cadence to none of them, and the two cheapest — the ones most often repeated elsewhere as monthly rates — appear only beside a new-patient discount that its own affiliate page describes as money off a three-month package. Its own undiscounted floors are higher, and they are on its own pages too. A figure with no period attached is not a price, and it cannot be compared with one.

But the math has two leaks the pitch doesn't price in.

Leak 1 — you may be buying proportionally less benefit. GLP-1 drugs follow a dose-response curve: lower doses do less. In a semaglutide dose-ranging trial, the lowest dose produced the smallest weight loss ⁴, and tirzepatide's pivotal obesity trial showed higher doses delivering more weight loss than lower ones ⁵. A microdose sits at the very bottom of that curve — sometimes below the lowest dose ever formally studied. Paying less to get proportionally less (or, at a true microdose, possibly very little) isn't the bargain a flat "cheaper per month" makes it sound.

Leak 2 — you may be paying in risk instead of dollars. The savings on compounded product come bundled with documented sourcing and preparation problems. A pharmacovigilance analysis of compounded GLP-1 agonists using the FDA Adverse Event Reporting System (FAERS) found markedly elevated reporting odds for preparation errors (reporting odds ratio about 48.9), contamination (about 19.0), compounding issues (about 8.5), and prescribing errors (about 4.5), along with more reports of abdominal pain, cholecystitis, and hospitalization ⁶. That's a spontaneous-reporting database — association, not proof of causation — but it's exactly the signal you'd want flagged before choosing a route on price alone. "Cheaper" and "safer" are not the same axis.

The hidden line items

The advertised monthly price is rarely the whole cost. Budget honestly for:

• •Clinician visits and intake fees. A legitimate route involves a licensed clinician actually reviewing your case — telehealth platforms bundle or charge for this, and a supervised plan with your own physician adds visit costs.
• •Lab work and monitoring. Baseline and follow-up labs add cost but are part of doing this responsibly, not an optional extra.
• •Supplies. Syringes, alcohol swabs, sharps disposal — small, but real and recurring.
• •The cost of getting it wrong. If a compounded vial's concentration is uncertain and you measure a "microdose" out of it, a wrong-concentration vial can turn a microdose into a large overdose — a safety cost, not just a financial one ⁶.

The legal status is part of the price

Part of why compounded product is cheaper is that it sits outside the standardized manufacturing and quality controls of an FDA-approved drug. Compounding became widespread under shortage rules that temporarily allowed broader compounding; as those shortages resolved, the legal footing for routine compounding narrowed considerably ³ — and in 2026 the FDA moved to close the bulk-compounding pathway entirely, which we track in is compounded microdose GLP-1 still legal in 2026. The clinical-pharmacy consensus is cautious: a position opinion on compounded incretins stresses they should be considered carefully and primarily in the context of genuine access problems — not as a casual cheaper alternative ⁷. A rock-bottom price from an unvetted source often reflects that it's the gray market, where the safety data are worst.

A sourcing-vetting checklist before you pay anything

If cost has pushed you toward a compounded or microdosing route, vet hard before you pay — our individual provider reviews answer most of the following for the companies we track, and you should ask any provider they do not cover:

• •Is a licensed clinician genuinely reviewing your case, or is it a rubber-stamp intake?
• •Is the product an FDA-approved branded drug or compounded? If compounded, which 503A or 503B pharmacy makes it — and will they name it?
• •Will they tell you the exact concentration of what they ship? (Essential if you intend to measure a fraction — and the difference between a microdose and an overdose.)
• •What monitoring, labs, and follow-up are included in the price?
• •Are there hidden intake, membership, or renewal fees on top of the advertised monthly number?

There is a shortcut through most of that list. Take whatever figure a provider is advertising, and work the plan through a year with the prepay rung, the introductory month, the membership and the billing cycle all counted before you compare it with anyone else's. If a provider can't answer those plainly, that's a red flag — and a reason to walk, no matter how low the price. We grade providers on exactly these points on our GLP-1 microdose rankings hub, and walk through the full evaluation checklist in best microdose GLP-1 telehealth providers (2026).

If tirzepatide is the molecule you are pricing specifically, we broke the spread out separately — the rate providers lead with, the median, and why the structure that sounds cheapest for a low dose is not — in what a tirzepatide microdose actually costs.

The honest bottom line

Microdosing GLP-1 grew up as the cheap alternative to brand-name therapy, but that gap has mostly closed: compounded routes commonly run $155–$500/month, and brand self-pay programs now run about $149–$499/month (October 2026), with the lowest brand strengths the cheapest. But the low price isn't free money. The dose-response evidence says a microdose likely buys proportionally less benefit ^4,5, the compounded supply chain carries documented safety signals ⁶, and the cheapest sources are the least regulated ^3,7. If you proceed, do it with a qualified clinician and a legitimately sourced, known-concentration product — and treat any unusually cheap, unvetted source as the warning it is.

For the full evidence picture, start with our pillar Microdosing GLP-1: what the evidence actually shows. If you've decided to proceed, how to get microdosing tirzepatide walks through the real routes, and is compounded / microdosed GLP-1 safe covers the safety case in depth. See also microdosing tirzepatide: what the evidence actually says, and weigh the value question against low-dose vs full-dose GLP-1. Compare vetted options on the GLP-1 microdose rankings hub.